Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"Cetuximab"”.
-
Methylation of Egfr By Arginine Methyltransferase Prmt1 Enhances Egfr Signaling and Cetuximab Resistance
… of therapeutic EGFR monoclonal antibody, cetuximab. EGFR methylation level also correlates with higher recurrence rate after cetuximab treatment and poorer overall survival in colorectal cancer patients. These data suggest that R198/R200 methylation plays important role in regulating EGFR …
-
Novel Functions of Cetuximab In Egfr-Targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation
… of head and neck cancers. The anti-EGFR antibody cetuximab has been approved by the FDA for the treatment of head and neck cancers, however, only a small fraction of patients respond to cetuximab treatment. Further investigation to understand the mechanisms underlying cetuximab-mediated …
-
Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab
… di cancro al colon trattate dopo trattamento con cetuximab, un farmaco anti-tumorale diretto contro il recettore EGFR. In particolare, la via di EGFR è stata accostata alla biogenesi dei microRNAs e in aggiunta alla comunicazione intercellulare. Le due linee cellulari analizzate erano le Caco-2 …
-
JAG1 Blockade With oHSV Polarizes Macrophages to Create a Unique Vulnerability for Cetuximab-Mediated Senolysis of Glioma Cells
… death, which created a unique vulnerability for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic response of OncoD-0J1 as a monotherapy.</p>
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… the targeted therapy. The EGFR-targeted therapy cetuximab is a chimeric IgG1 monoclonal antibody which binds to the ligand binding domain of the receptor, thereby preventing activation of survival signalling via the MAPK pathway mediated by phosphorylation of EGFR. Cetuximab has been approved for …
-
Pancreatic Ribonuclease Functions As An Epidermal Growth Factor Receptor Ligand Independently of Its Enzyme Activity and Contributes to Cetuximab Resistance
… Strikingly, hRNase5 also enhances resistance to cetuximab therapy in pancreatic cancer. Thus, there may be an interplay between serum RNase and overexpressed EGFR in human cancers, especially in pancreatic cancer, that leads to aggressive cancer behaviors. Our findings uncover a potential …
-
Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma
… a comparative biodistribution study of 64Cu-DOTAcetuximab in subcutaneous (SQ) tumor and MA mouse models. A mouse xenograft model of bilateral SQ tumors that express epidermal growth factor receptor (EGFR) was established by SQ injections of NUGC-4 and MKN-45 gastric cancer cells into either …
-
The significance of the EGFR pathway in malignant pleural mesothelioma
… and BRAF mutations. Cells were incubated with Cetuximab, Gefitinib, Rapamycin, Ku0063794 (MTOR kinase inhibitor) and Celecoxib as single agents and in combinations and analysed using the MTS assay.ResultsPositive 5-LOX expression was seen in 73% and positive 12-LOX expression was seen in 83% of …
-
Copper-64 radiopharmaceuticals for receptor-mediated tumor imaging and radiotherapy
… acetate and the EGFR-antibody 64Cu-DOTA-cetuximab, the tumor suppressor protein p53 was identified as a mediator of the nuclear transport of copper. 64Cu-DOTA-cetuximab was also utilized in five cervical cancer cell lines with a wide range of EGFR expression. EGFR quantification by …
-
Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC)
… polmonare. Sono stati utilizzati, a tale scopo, cetuximab, anticorpo monoclonale diretto contro l'EGFR e trastuzumab, anticorpo monoclonale diretto contro l'HER-2, a diverse concentrazioni per 72 h. Mediante il saggio di proliferazione MTT (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide) …
-
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies: Examples and Estimation Method Performance Differences
… which focused on the population PK modeling of cetuximab, and the evaluation of different estimation methods for population PK modeling of therapeutic mAbs with nonlinear PK characteristics.</p> <p> Cetuximab is a therapeutic mAb directed against the epidermal growth factor receptor and is …
-
Evaluating Cost Effectiveness of Precision Cancer Medicine Approaches and The Economic Burden of Colorectal Cancer
… of KRAS/NRAS mutational status for guiding cetuximab or panitumumab therapy is inconclusive.<br/><br/>Overall, the systematic review revealed that there was a paucity of cost-effectiveness studies in CRC to support biomarker-enriched PCM approaches.<br/><br/>To discern the real-world impact …
-
Ube4B Levels Determine The Efficacy of Egfr and Stat5 Inhibitors In Treatment Resistant Neuroblastoma
… STAT5a levels. We observed that treatment with Cetuximab, a therapeutic antibody targeting the EGFR, significantly inhibited the proliferation of neuroblastoma cells depleted of UBE4B. Addition of a STAT5 inhibitor potentiated the Cetuximab-induced inhibition of proliferation, reduced migration, …
-
New protein engineering approaches for potentiating and studying antibody-based EGFR antagonism
… research tool, a minimally modified verstion of cetuximab called "mCetux", which essentially enables in vivo experiments of cetuximab. I apply this antibody tool in vitro and in vivo in a new and highly relevant model system for colorectal cancer and subsequently discuss future opportunities for …
-
Epidermal growth factor and Transforming growth factor α motogenic activities are mediated by Epidermal growth factor receptor : Identification of signalling pathways involved in head and neck cancer
… EGFR target for this neoplasm is the drug Cetuximab. Cetuximab can only be used where there is an over-expression of EGFR. Cetuximab works by competing with the ligands Epidermal Growth Factor (EGF) and Transforming Growth Factor alpha (TGFα) to bind the extracellular domain of EGFR. …
-
Design and applications of antibody mimics against epidermal growth factor receptor
… and identifying EGFR epitope region where Cetuximab CDR binds and modifying sequences using knob-socket computational model. The binding of antibody mimics were first analyzed by using MOE to obtain the binding energy, total and preserved interactions as compared to the interactions between …
-
Analisi d'espressione genica, analisi dati e metodologie di modellistica computazionale nel cancro e i disturbi neurodegenerativi
… della struttura di fusione proteina H-cetuximab fornita dalla società Etna Biotech, sono stati utilizzati strumenti bioinformatici. Il terzo e ultimo argomento di questa tesi mira a fornire un workflow completo per l'analisi dei dati RNA-seq. Partendo dai dati di sequenziamento di …
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
… erlotinib, the monoclonal antibody against EGFR cetuximab, and the multi-target tyrosine kinase inhibitor dasatinib. Significantly higher EGFR expression was detected in TNBC compared to HER-2 positive breast cancer cell lines. EGF treatment stimulated phospho-EGFR which was inhibited by …
-
Car-Modified T Cells Capable of Distinguishing Normal Cells From Malignant Cells
… toxicity, EGFR-specific CAR generated from cetuximab, Cetux-CAR, was transiently expressed in T cells by RNA-modification. RNA-modified CAR<sup>+</sup> T cells demonstrated similar cytotoxicity against EGFR<sup>+</sup> cells, including normal renal cells, as DNA-modified CAR<sup>+</sup> T …
-
Novel Approaches in Pancreatic Cancer Treatment: Bridging Mechanics, Cells, and Immunity
… growth factor (EGFR) monoclonal antibody, cetuximab- which is frequently used in cancer immunotherapy. Together, our findings address challenges in the delivery of a range of therapeutics while simultaneously exposing challenges like off-target damage. In conclusion, this study presents a …
Page 1 of 2